Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.
G IacobellisMarco Giorgio BaroniPublished in: Journal of endocrinological investigation (2021)
Epicardial adipose tissue is a novel cardiovascular risk factor. It plays a role in the progression of coronary artery disease, heart failure and atrial fibrillation. Given its rapid metabolism, clinical measurability, and modifiability, epicardial fat works well as therapeutic target of drugs modulating the adipose tissue. Epicardial fat responds to glucagon-like peptide 1 receptor agonists (GLP1A) and sodium glucose co-transporter 2 inhibitors (SGLT2i). GLP-1A and SGLT2i provide weight loss and cardiovascular protective effects beyond diabetes control, as recently demonstrated. The potential of modulating the epicardial fat morphology and genetic profile with targeted pharmacological agents can open new avenues in the pharmacotherapy of diabetes and obesity, with particular focus on cardiovascular risk reduction.
Keyphrases
- adipose tissue
- insulin resistance
- weight loss
- heart failure
- type diabetes
- atrial fibrillation
- coronary artery disease
- high fat diet
- cardiovascular disease
- glycemic control
- bariatric surgery
- metabolic syndrome
- signaling pathway
- fatty acid
- left ventricular
- genome wide
- direct oral anticoagulants
- cardiovascular events
- left atrial
- body mass index
- risk assessment
- coronary artery bypass grafting
- climate change
- human health
- cancer therapy
- acute coronary syndrome
- aortic valve
- mitral valve
- gastric bypass